Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Innate lymphoid cells as regulators of the tumor microenvironment.

Tugues S, Ducimetiere L, Friebel E, Becher B.

Semin Immunol. 2019 Mar 11. pii: S1044-5323(18)30121-0. doi: 10.1016/j.smim.2019.03.002. [Epub ahead of print] Review.

PMID:
30871769
2.

Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells.

Tugues S, Amorim A, Spath S, Martin-Blondel G, Schreiner B, De Feo D, Lutz M, Guscetti F, Apostolova P, Haftmann C, Hasselblatt P, Núñez NG, Hottiger MO, van den Broek M, Manz MG, Zeiser R, Becher B.

Sci Transl Med. 2018 Nov 28;10(469). pii: eaat8410. doi: 10.1126/scitranslmed.aat8410.

PMID:
30487251
3.

CSF1R-dependent myeloid cells are required for NK‑mediated control of metastasis.

Beffinger M, Tallón de Lara P, Tugues S, Vermeer M, Montagnolo Y, Ohs I, Cecconi V, Lucchiari G, Gagliardi A, Misljencevic N, Sutton J, Spörri R, Becher B, Gupta A, van den Broek M.

JCI Insight. 2018 May 17;3(10). pii: 97792. doi: 10.1172/jci.insight.97792. eCollection 2018 May 17.

4.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
5.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

6.

Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade.

Ohs I, Ducimetière L, Marinho J, Kulig P, Becher B, Tugues S.

Cancer Res. 2017 Dec 15;77(24):7059-7071. doi: 10.1158/0008-5472.CAN-17-1032. Epub 2017 Oct 17.

7.

Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs.

Nussbaum K, Burkhard SH, Ohs I, Mair F, Klose CSN, Arnold SJ, Diefenbach A, Tugues S, Becher B.

J Exp Med. 2017 Aug 7;214(8):2331-2347. doi: 10.1084/jem.20162031. Epub 2017 Jul 11.

8.

Corrigendum: Interleukin-12 bypasses common gamma-chain signalling in emergency natural killer cell lymphopoiesis.

Ohs I, van den Broek M, Nussbaum K, Münz C, Arnold SJ, Quezada SA, Tugues S, Becher B.

Nat Commun. 2017 Apr 4;8:15185. doi: 10.1038/ncomms15185. No abstract available.

9.

Interleukin-12 bypasses common gamma-chain signalling in emergency natural killer cell lymphopoiesis.

Ohs I, van den Broek M, Nussbaum K, Münz C, Arnold SJ, Quezada SA, Tugues S, Becher B.

Nat Commun. 2016 Dec 16;7:13708. doi: 10.1038/ncomms13708.

10.

GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation.

Becher B, Tugues S, Greter M.

Immunity. 2016 Nov 15;45(5):963-973. doi: 10.1016/j.immuni.2016.10.026. Review.

11.

Histidine-rich glycoprotein blocks collagen-binding integrins and adhesion of endothelial cells through low-affinity interaction with α2 integrin.

Roche F, Sipilä K, Honjo S, Johansson S, Tugues S, Heino J, Claesson-Welsh L.

Matrix Biol. 2015 Oct;48:89-99. doi: 10.1016/j.matbio.2015.06.002. Epub 2015 Jun 5.

PMID:
26051322
12.

Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes.

Tugues S, Roche F, Noguer O, Orlova A, Bhoi S, Padhan N, Akerud P, Honjo S, Selvaraju RK, Mazzone M, Tolmachev V, Claesson-Welsh L.

PLoS One. 2014 Sep 22;9(9):e107483. doi: 10.1371/journal.pone.0107483. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0118636.

13.

New insights into IL-12-mediated tumor suppression.

Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B.

Cell Death Differ. 2015 Feb;22(2):237-46. doi: 10.1038/cdd.2014.134. Epub 2014 Sep 5. Review.

14.

Tetraspanin CD63 promotes vascular endothelial growth factor receptor 2-β1 integrin complex formation, thereby regulating activation and downstream signaling in endothelial cells in vitro and in vivo.

Tugues S, Honjo S, König C, Padhan N, Kroon J, Gualandi L, Li X, Barkefors I, Thijssen VL, Griffioen AW, Claesson-Welsh L.

J Biol Chem. 2013 Jun 28;288(26):19060-71. doi: 10.1074/jbc.M113.468199. Epub 2013 Apr 30.

15.

Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization.

Tugues S, Honjo S, König C, Noguer O, Hedlund M, Botling J, Deschoemaeker S, Wenes M, Rolny C, Jahnen-Dechent W, Mazzone M, Claesson-Welsh L.

Cancer Res. 2012 Apr 15;72(8):1953-63. doi: 10.1158/0008-5472.CAN-11-2194. Epub 2012 Feb 28.

16.

Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats.

Ribera J, Pauta M, Melgar-Lesmes P, Tugues S, Fernández-Varo G, Held KF, Soria G, Tudela R, Planas AM, Fernández-Hernando C, Arroyo V, Jiménez W, Morales-Ruiz M.

Gut. 2013 Jan;62(1):138-45. doi: 10.1136/gutjnl-2011-300703. Epub 2012 Jan 20.

PMID:
22267600
17.

Signal transduction by vascular endothelial growth factor receptors.

Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L.

Biochem J. 2011 Jul 15;437(2):169-83. doi: 10.1042/BJ20110301. Review.

PMID:
21711246
18.

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.

Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L.

Mol Aspects Med. 2011 Apr;32(2):88-111. doi: 10.1016/j.mam.2011.04.004. Epub 2011 May 6. Review.

PMID:
21565214
19.

Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice.

Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, Libbrecht L, Olievier K, Schroyen B, Reynaert H, van Grunsven LA, Blomme B, Coulon S, Heindryckx F, De Vos M, Stassen JM, Vinckier S, Altamirano J, Bataller R, Carmeliet P, Van Vlierberghe H, Colle I, Morales-Ruiz M.

Hepatology. 2011 May;53(5):1629-40. doi: 10.1002/hep.24238.

PMID:
21520176
20.

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.

Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, De Mol M, Salomäki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, Carmeliet P.

Cancer Cell. 2011 Jan 18;19(1):31-44. doi: 10.1016/j.ccr.2010.11.009. Epub 2011 Jan 6.

21.

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I, Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic JM, Jiménez W, Noël A, Giacca M, Colle I, Foidart JM, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P.

Cell. 2010 Apr 2;141(1):178-90. doi: 10.1016/j.cell.2010.02.039.

22.

Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats.

Melgar-Lesmes P, Tugues S, Ros J, Fernández-Varo G, Morales-Ruiz M, Rodés J, Jiménez W.

Gut. 2009 Feb;58(2):285-92. doi: 10.1136/gut.2008.155028. Epub 2008 Oct 31.

PMID:
18978178
23.

Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.

Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jiménez W.

J Pharmacol Exp Ther. 2008 Feb;324(2):475-83. Epub 2007 Nov 20.

24.

Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.

Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, Friedman SL, Carmeliet P, Jiménez W, Morales-Ruiz M.

Hepatology. 2007 Dec;46(6):1919-26.

PMID:
17935226
25.

Gene transduction of an active mutant of akt exerts cytoprotection and reduces graft injury after liver transplantation.

Morales-Ruiz M, Fondevila C, Muñoz-Luque J, Tugues S, Rodríguez-Laiz G, Cejudo-Martín P, Romero JM, Navasa M, Fuster J, Arroyo V, Sessa WC, García-Valdecasas JC, Jiménez W.

Am J Transplant. 2007 Apr;7(4):769-78.

26.

Impaired extracellular matrix degradation in aortic vessels of cirrhotic rats.

Fernández-Varo G, Morales-Ruiz M, Ros J, Tugues S, Muñoz-Luque J, Casals G, Arroyo V, Rodés J, Jiménez W.

J Hepatol. 2007 Mar;46(3):440-6. Epub 2006 Nov 13.

PMID:
17156884
27.

Microarray analysis of endothelial differentially expressed genes in liver of cirrhotic rats.

Tugues S, Morales-Ruiz M, Fernandez-Varo G, Ros J, Arteta D, Muñoz-Luque J, Arroyo V, Rodés J, Jiménez W.

Gastroenterology. 2005 Nov;129(5):1686-95.

PMID:
16285966
28.

Ascites from cirrhotic patients induces angiogenesis through the phosphoinositide 3-kinase/Akt signaling pathway.

Morales-Ruiz M, Tugues S, Cejudo-Martín P, Ros J, Melgar-Lesmes P, Fernández-Llama P, Arroyo V, Rodés J, Jiménez W.

J Hepatol. 2005 Jul;43(1):85-91. Epub 2005 Apr 12.

PMID:
15890430
29.

Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats.

Morales-Ruiz M, Cejudo-Martín P, Fernández-Varo G, Tugues S, Ros J, Angeli P, Rivera F, Arroyo V, Rodés J, Sessa WC, Jiménez W.

Gastroenterology. 2003 Aug;125(2):522-31.

PMID:
12891555

Supplemental Content

Loading ...
Support Center